The US bought up 90% of the world's supply of remdesivir for the next 3 months, and patents mean many countries won't be able to get any

• The US has struck a deal with Gilead Sciences to purchase more than 90% of the global supply of remdesivir.
• Remdesivir has been shown to help moderately ill patients recover more quickly from COVID-19, and is only of the only treatments that has been found to be as effective. 
• HHS secretary Alex Azar called it an "amazing deal," but it leaves many countries with few options.
• The treatment, which was previously donated by Gilead, has now been priced at $2,340 per course for developed nations, including the US. 
• Visit Business Insider's homepage for more stories.

The US has purchased more than 90% of the world's supply of remdesivir, the only proven treatment for COVID-19, which will leave little for the rest of the world for at least the next three months. 

Gilead Sciences, the US-based company that makes the drug, agreed to sell more than 500,000 treatment courses to the US until September, which is almost the entire amount it has the ability to produce.

See the rest of the story at Business Insider

See Also:

• California, whose coronavirus response was hailed as a success story, is now seeing 5,000-plus cases each day. Here's what went wrong.
• WHO: 'The worst is yet to come' and the coronavirus pandemic is 'speeding up' because some countries aren't taking it seriously enough
• Gilead turned a failed Ebola drug into the first effective coronavirus treatment. Here's everything you need to know about remdesivir.

from Feedburner https://ift.tt/3dPNv3O